ANDROCUR TABLET

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

CYPROTERONE ACETATE

から入手可能:

BAYER INC

ATCコード:

G03HA01

INN（国際名）:

CYPROTERONE

投薬量:

50MG

医薬品形態:

TABLET

構図:

CYPROTERONE ACETATE 50MG

投与経路:

ORAL

パッケージ内のユニット:

60

処方タイプ:

Prescription

治療領域:

OTHER MISCELLANEOUS THERAPEUTIC AGENTS

製品概要:

Active ingredient group (AIG) number: 0116806001; AHFS:

認証ステータス:

APPROVED

承認日:

2007-03-21

製品の特徴

_ANDROCUR Product Monograph_
Page 1 of 32
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ANDROCUR
®
cyproterone acetate tablets
50 mg
PR
ANDROCUR
® DEPOT
Cyproterone acetate injection
100 mg/mL
Antiandrogen
Bayer Inc.
2920 Matheson Blvd East,
Mississauga, Ontario
L4W 5R6
www.bayer.ca
Date of Initial Approval:
April 26, 1985
Date of Revision:
May 13, 2021
Submission Control No: 245903
©
2021, Bayer Inc.
® TM see www.bayer.ca/tm-mc.
_ANDROCUR Product Monograph_
Page 2 of 32
Sections or subsections that are not applicable at the time of
authorization are not listed.
TABLE OF CONTENTS ...................................................................................................................2
PART I: HEALTH PROFESSIONAL
INFORMATION...............................................................................................................
3
1.
INDICATIONS
................................................................................................................................................................
3
2.
CONTRAINDICATIONS
.................................................................................................................................................
3
3.
SERIOUS
WARNINGS
AND
PRECAUTIONS
.................................................................................................................
3
4.
DOSAGE
AND
ADMINISTRATION................................................................................................................................
3
4.1 Dosing Considerations
..........................................................................................................................................
3
4.2 Recommended Dose and Dosage
Adjustment....................................................................................................
3
4.3 Reconstitution
.......................................................................................................................................................
4
4.4 Administration
.........